Tag:
tofacitinib
Latest Headlines
Latest Headlines
Payers likely to throw up hurdles to Pfizer's new RA drug
You know that old adage: The one with the gold makes the rules? For the latest exhibit, look no further than Pfizer's anticipated rheumatoid arthritis treatment tofacitinib.
Payers likely to throw up hurdles to Pfizer's new RA drug
The FDA may be a new drug's biggest hurdle, but payers are throwing up more obstacles as high-tech treatments get pricier and healthcare costs keep rising.
Incyte rides wave after Pfizer's FDA panel nod
Incyte's shares jumped this week after agency advisers backed approval of Pfizer's potential blockbuster JAK inhibitor for rheumatoid arthritis.
UPDATED: FDA advisers sign off on Pfizer's arthritis pill
An FDA advisory committee endorsed the company's drug, tofacitinib, as a safe and effective treatment for patients with rheumatoid arthritis.
FDA harps on risks of Pfizer's tofacitinib as panel looms
FDA staffers raised concerns about increased risks of malignant cancers--particularly lymphomas--and infections tied to the drug.
Pfizer faces crucial panel vote on blockbuster hopeful tofacitinib
Next week FDA advisers will take their turn dissecting the upsides and downsides of the first-in-class drug for rheumatoid arthritis.
Pfizer turns to late-stage pipeline to make up for Lipitor crash
The pharma giant is staying focused on the fate of a trio of late-stage therapies that are desperately needed to fill a growing gap.
Pfizer faces bumps in road with potential blockbuster RA pill
Pfizer ( $PFE ) has highlighted its experimental rheumatoid arthritis (RA) pill tofacitinib among the standouts in its pipeline, but a new survey shows that some doctors and payers might not share the pharma giant's exuberance about the program.
Pfizer dumps rights to RA drugs from biotech Ablynx
Belgian biotech Ablynx took a hit this morning after Pfizer ( $PFE ) let go of its rights to the smaller firm's nanobody compounds for treating rheumatoid arthritis. Pfizer dumped the program as part
Pfizer lays out its pivotal case for oral RA pill against blockbuster Humira
Pfizer ( $PFE ) today laid out data from a slate of studies on its rheumatoid arthritis pill tofacitinib--a potential blockbuster--building a case that the oral drug is comparable to Humira.
